During a median follow-up of @ months ( interquartile range @-@ months ) , mean within-group eGFR change from baseline was +@ mL/min/@ @ m for TDF , -@ mL/min/@ @ m for FTC-TDF , and +@ mL/min/@ @ m for placebo , translating into average declines in eGFR attributable to PrEP vs placebo of -@ mL/min/@ @ m ( @ % CI , -@ to -@ ; P = @ ) for TDF and -@ mL/min/@ @ m ( @ % CI , -@ to -@ ; P < @ ) for FTC-TDF .